| [编纂]之 编纂]數目 | . | [编纂]股股份(視乎[編纂]行使與否而 | | --- | --- | --- | | | | 定) | | [编纂]數目 | .. | [編纂]股股份(可予[編纂]) | | [編纂]數目 | .. | 編纂 股股份(可予編纂)及視乎 編纂] | | | | 行使與否而定) | | 最高 编纂] | : | 每股[編纂][編纂]港元,另加1.0% | | | | 經紀佣金、0.0027％證監會交易徵 | | | | 費 · 0.00565% 香港聯交所交易費及 | | | | 0.00015%會財局交易徵費(須於申請 | | | | 時以港元繳足,多繳股款可予退還) | | 面值 | : | 母股股份[0.000002]美元 | | 股份代號 | : | [禮畫] | | 聯席保薦人 | | | | 新闻 2019 11:22 11:22 11 | | Anton and and response . | 2025年9月4日，来自广东深圳南山区的健康160国际有限公司160 Health International Limited（以下简称"健康160"）在港交所披露 ...

智通财经APP获悉，据港交所9月4日披露，健康160国际有限公司(以下简称：健康160)通过港交所主板 上市聆讯，申万宏源香港、清科资本为其联席保荐人。 | 鳥纂]之[編纂]數目 : [編纂]股股份(視乎[編纂]行使與否而 | 定) | | --- | --- | | [編纂]數目 .. | [編纂]股股份(可予[編纂]) | | [編纂]數目 : | [編纂]股股份(可予[編纂]及視乎[編纂] | | | 行使與否而定) | | 最高 编纂] : | 每股[編纂][編纂]港元,另加1.0% | | | 經紀佣金、0.0027%證監會交易徵 | | | 費、0.00565%香港聯交所交易費及 | | | 0.00015%會財局交易徵費(須於申請 | | | 時以港元繳足,多繳股款可予退還) | | . 面值 | 每股股份[0.000002]美元 | | 股份代號 | : [編纂] | 据招股书，健康160是富有经验的中国医药健康用品批发商及领先的数字医疗综合服务提供商。该公司 为客户提供各种医药健康用品，以及全面的数字医疗健康解决方案。在批发及零售模式下，提供一系列 优质的医药健康用品，以满足客户的不同需求。 ...

据港交所9月4日披露，健康160国际有限公司(以下简称：健康160)通过港交所主板上市聆讯，申万宏源 香港、清科资本为其联席保荐人。 据招股书，健康160是富有经验的中国医药健康用品批发商及领先的数字医疗综合服务提供商。该公司 为客户提供各种医药健康用品，以及全面的数字医疗健康解决方案。在批发及零售模式下，提供一系列 优质的医药健康用品，以满足客户的不同需求。此外，该公司亦通过在线医疗健康服务平台-健康160平 台提供数字医疗健康解决方案，赋能整个医疗健康产业链上的各平台参与方(主要包括企业客户、医疗 卫生机构、医护人员及个人用户和第三方商户)，推动中国医疗健康行业的数字化转型。 在提供数字化医疗健康解决方案时，该公司已开发健康160平台，该服务平台通过整合在线及线下渠道 的医疗健康服务，有效地连接医疗健康机构，医护人员及个人用户。平台提供多样化的医疗健康服务， 包括严肃医疗及消费医疗服务。该公司对数字医疗健康解决方案中采用有效的变现策略，来从各平台参 与方产生收入，从而构成该公司的重要收入来源。根据弗若斯特沙利文的资料，按2024年通过平台挂号 的数量计算;截至2024年12月31日合作医院数量计算;截至2 ...

Core Insights - The healthcare industry is experiencing significant developments in the first half of 2025, with companies like "Health 160" and "Weimai" filing for IPOs, while others like "Good Mood" and "Weimai" secure substantial financing [1][4][9]. Company Summaries - "Health 160" has faced cash flow challenges, with negative operating cash flow for four consecutive years and only 46.11 million RMB in cash against 70.2 million RMB in debts due within 90 days. The company's revenue heavily relies on low-margin drug sales, which account for over 70% of its income, resulting in a gross margin of only 1.9% [5]. - "Weimai" has submitted its prospectus for a main board listing, reporting revenues of 512 million RMB, 627 million RMB, and 653 million RMB from 2022 to 2024, with gross margins increasing from 17.2% to 19.9% during the same period. However, the company has also reported significant losses, with adjusted net losses narrowing from 4.14 billion RMB in 2022 to 1.93 billion RMB in 2024 [6][8]. - "Good Mood," an internet psychological healthcare platform, completed a financing round of several hundred million RMB, with investments from institutions like CITIC Medical Fund and Xu Zhou Industrial Investment [9][10]. - "Lingjian" announced an E-round financing of several hundred million RMB, backed by Wuxi Venture Capital Group and Binhu Industrial Group, focusing on providing services to over 50,000 dental and medical beauty institutions [11][12]. Industry Trends - The digital health sector is evolving with AI integration, as seen in partnerships like that of "Weimai" and Alibaba Cloud, aiming to build a comprehensive AI healthcare infrastructure [15][17]. - The launch of "Ping An Chip Doctor" by Ping An Health represents a significant innovation in AI-driven healthcare services, enhancing accessibility and efficiency in patient interactions [24][26]. - The introduction of AI applications like "Anzheng Er," which combines advanced reasoning capabilities with healthcare services, indicates a trend towards more personalized and efficient patient care [26][27]. - The healthcare landscape is shifting towards a more integrated model, with companies like Meituan Health and JD Health leveraging AI to create comprehensive service ecosystems that connect online and offline healthcare services [20][22].

Core Viewpoint - Health 160 has submitted its third application to the Hong Kong Stock Exchange, with sponsors including Shenwan Hongyuan Hong Kong and QK Capital [1]. Company Overview - Health 160 is a Chinese wholesale distributor of medical and health products and a provider of digital healthcare solutions, offering a range of medical health products to enterprise clients and retail customers [4]. - The company operates an online healthcare service platform, Health 160, which facilitates digital healthcare solutions across the healthcare industry, empowering various stakeholders including enterprise clients, healthcare institutions, healthcare professionals, individual users, and third-party merchants [4]. Service Expansion - As of December 31, 2024, Health 160 has expanded its services to over 260 cities nationwide and established 11 regional operation centers in key areas such as Shenzhen, Beijing, Shanghai, and Guangzhou [5]. - The platform connects over 44,600 healthcare institutions, including more than 14,400 hospitals (of which 3,424 are tertiary hospitals) and over 30,200 grassroots healthcare institutions [5]. - Health 160 collaborates with over 898,200 healthcare professionals and has a substantial user base, with approximately 54.1 million registered individual users and an average of 3.3 million monthly active users in 2024 [5]. Financial Performance - The company's revenue increased from approximately 526 million RMB in 2022 to about 629 million RMB in 2023, reflecting a growth of 19.6% [5]. - Revenue is expected to remain relatively stable, projected at 621 million RMB for 2024 [5]. - Health 160 recorded annual losses of approximately 120 million RMB, 106.2 million RMB, and 108.2 million RMB for the years 2022, 2023, and 2024, respectively [6][7].